구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Adebrelimab combined with Apatinib (Adebrelimab combined with Apatinib) Tang-Du Hospital·SCLC 30 trials |
|---|---|
Overview Program | Adebrelimab combined with Apatinib |
Overview Company | Tang-Du Hospital |
Overview Modality | ANTIBODY |
Overview Target | SCLC |
Overview Indication | SCLC |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Biomarker | PD-L1 expression |
PK/PD Experiment | PD |
Toxicology Major finding | Case Report: Adebrelimab-associated suspected immune-related myocarditis with myositis/myasthenia gravis overlap syndrome (IM3OS): A rapidly fatal case and clinical implications.. This article reports a case of a 72-year-old male with intrahepatic cholangiocarcinoma who developed acute symptoms-including chest tightness, muscle weakness, ophthalmoplegia, and dyspnea-3 days after receiving the seco… |
Clinical Safety signal | Case Report: Adebrelimab-associated suspected immune-related myocarditis with myositis/myasthenia gravis overlap syndrome (IM3OS): A rapidly fatal case and clinical implications.. This article reports a case of a 72-year-old male with intrahepatic cholangiocarcinoma who developed acute symptoms-including chest tightness, muscle weakness, ophthalmoplegia, and dyspnea-3 days after receiving the seco… |
Clinical Program phase | PHASE_2 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Adebrelimab combined with Apatinib (Adebrelimab combined with Apatinib) Tang-Du Hospital·SCLC 30 trials |
|---|---|
Overview Program | Adebrelimab combined with Apatinib |
Overview Company | Tang-Du Hospital |
Overview Modality | ANTIBODY |
Overview Target | SCLC |
Overview Indication | SCLC |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Biomarker | PD-L1 expression |
PK/PD Experiment | PD |
Toxicology Major finding | Case Report: Adebrelimab-associated suspected immune-related myocarditis with myositis/myasthenia gravis overlap syndrome (IM3OS): A rapidly fatal case and clinical implications.. This article reports a case of a 72-year-old male with intrahepatic cholangiocarcinoma who developed acute symptoms-including chest tightness, muscle weakness, ophthalmoplegia, and dyspnea-3 days after receiving the seco… |
Clinical Safety signal | Case Report: Adebrelimab-associated suspected immune-related myocarditis with myositis/myasthenia gravis overlap syndrome (IM3OS): A rapidly fatal case and clinical implications.. This article reports a case of a 72-year-old male with intrahepatic cholangiocarcinoma who developed acute symptoms-including chest tightness, muscle weakness, ophthalmoplegia, and dyspnea-3 days after receiving the seco… |
Clinical Program phase | PHASE_2 |
추천 비교
추천 비교